Original title: 70 new drugs of national medical insurance: the price of drugs containing hepatitis B dropped by 60%
4hw.com.cn today (November 28), the National Medical Security Bureau and the Ministry of human resources and social security released the complete version of the 2019 national directory of drugs for basic medical insurance, work injury insurance and maternity insurance, which contains 2709 drugs. Compared with 2017 edition, 218 drugs were transferred in, 154 drugs were transferred out, a net increase of 64. The new catalogue will be put into effect on January 1.
Through the latest negotiation, in the new version of the national medical insurance drug catalog, another 70 drugs have been added to the ranks of medical insurance reimbursement, and another 27 drugs' Renewal '. All 97 drugs will be included in the scope of class B drugs in the medical insurance catalog. These drugs are:
The drug adjustment is mainly through the negotiation of drug enterprises, which is the largest negotiation since the establishment of the medical insurance system in China.
In the negotiation, experts reviewed and voted to propose 128 alternative lists of negotiated drugs. After the enterprise confirmed the negotiation intention, 119 drugs were determined as new negotiated varieties. In addition, 31 of the varieties that were negotiated for access in 2017 needed to be negotiated again to determine whether the contract could be renewed. In total, there are 150 drugs in this negotiation. The number of new drugs and the total amount of drugs in the negotiation have reached a record high.
Cancer, hepatitis, diabetes & hellip; & hellip; these are no longer 'aristocratic' diseases
Most of the drugs successfully negotiated in this negotiation are newly marketed drugs with high clinical value in recent years, involving more than 10 clinical treatment fields such as cancer, rare disease, hepatitis, diabetes, MDR-TB, rheumatism immunity, cardio cerebrovascular, digestion, etc.
In terms of key areas, all five essential drugs were successfully negotiated, 22 anticancer drugs, 7 drugs for rare diseases, 14 drugs for chronic diseases (including diabetes, hepatitis B, rheumatoid arthritis, etc.) and 4 drugs for children were successfully negotiated.
From the perspective of innovation, most of the drugs successfully negotiated in this negotiation are new drugs launched in recent years, many of which are newly launched in 2018. Eight of the 12 major domestic innovative drugs have been negotiated.
'noble medicine' prescribes' civilian price '
Imported drugs are basically the 'lowest price in the world'
It is understood that the imported drugs included in the medical insurance this time are basically the lowest prices in the world, which has become a good news for patients.
In this negotiation, the price of 70 new drugs decreased by 60.7% on average, and that of 27 renewed drugs decreased by 26.4% on average. The individual burden of patients is reduced by more than 80%, and the individual drug burden is reduced by more than 95%.
Among them, the average decline rate of three kinds of hepatitis C treatment drugs is more than 85%, and the average decline rate of cancer, diabetes and other treatment drugs is about 65%, which makes' noble drugs' prescribe 'civilian price'.